Insider trade

Lantern Pharma (LTRN)10% owner sold ~$3

Kreis Leslie W., 10% owner at Lantern Pharma, sold ~$3 of Lantern Pharma shares.

~$3
Approx. value · 1 sh @ $3.40
55K
Holds after · shares reported
Traded
Jun 10, 2025
Filed
Jun 13, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. May 27, 2025Insider · 2 peopleInsiders: 10 sales (~$128K)
  2. May 28, 2025Insider · 2 peopleInsiders: 10 sales (~$86K)
  3. May 29, 2025Insider · 2 peopleInsiders: 10 sales (~$122K)
  4. Jun 10, 2025 · this disclosureInsider10% owner sold ~$3 of LTRN shares in the open market

What came next

  1. Jun 10, 2025Insider · 2 peopleInsiders: 9 sales (~$105)
  2. Jun 11, 2025Insider · 2 peopleInsiders: 10 sales (~$6K)
  3. Jun 13, 2025Insider · 2 peopleInsiders: 10 sales (~$247K)
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Lantern Pharma

OQRO holds no insider, Congress, fund or contract record for Lantern Pharma dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its LTRN page.

Other recent filings by Kreis Leslie W., 10% owner

The full history of Kreis Leslie W., 10% owner is on the profile page.

How this filing works

Other disclosures at Lantern Pharma

Everything OQRO holds on this company is on its LTRN page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data